Collection medium for whole blood

• US 4,782,026 A
• Filed: 02/25/1985
• Issued: 11/01/1988
• Est. Priority Date: 02/25/1985
• Status: Expired due to Term

• Current Assignee: Hemotec Incorporated
• Original Assignee: Hemotec Incorporated
• Inventors: Baugh, Robert F., Taylor, Cynthia A.
• Primary Examiner(s): NOT, DEFINED
• Assistant Examiner(s): Wallen, T. J.
• Application Number:
  US06/705,507
• Time in Patent Office: 1,345 Days
• Field of Search: 436/18, 436/69, 436/176, 435/13, 424/101
• US Class Current: 436/69
• CPC Class Codes: C12Q 1/56 involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
• CPC Class Codes: Y10T 436/108331 Preservative, buffer, anticoagulant or diluent

Abstract

An inhibitor of Platelet Factor 3 activity is included in a collection medium into which a whole blood sample is a collected. The inhibitor of Platelet Factor 3 activity, it has been discovered, prevents an initial drop in the activated clotting time measured during an assay test conducted on the whole blood sample collected in the medium. The discovery of the problem of the initial drop in the activated clotting time and the solution of including the inhibitor of Platelet Factor 3 activity is of considerable importance in heparin therapy, since the initial drop in the activated clotting time of heparinized blood is substantial. The inhibitor of Platelet Factor 3 activity can be included with a calcium chelating agent in the collection medium. Prostacylin and imidazole, which is an inhibitor of platelet thromboxane A2 synthesis, are effective inhibitors of Platelet Factor 3 activity.

Claims

1. A method of preventing an initial drop in the activated clotting time measured in a recalcified activated clotting time test performed on citrated whole blood collected from a patient, the initial drop otherwise normally occurring and substantially concluding within approximately thirty minutes after drawing the blood from the patient as a result of a platelet-related procoagulant activity initiated by drawing the blood, the method comprising:

collecting a sample of the whole blood in citrate, and approximately simultaneously

mixing an inhibitor of the initial drop with the blood sample, the inhibitor comprising one of a group consisting of a prostacyclin or imidazole.

2. A method as defined in claim 1 wherein:

the citrate is approximately a 3.8% sodium citrate concentration,

the inhibitor is prostacyclin, and

the prostacyclin is present in the approximate amount of 10 nanograms per milliliter of blood collected.

3. A method as defined in claim 1 wherein:

the citrate is approximately a 3.8% sodium citrate concentration,

the inhibitor is imidazole, and

the imidazole is present in an approximate concentration of 50 mM in the citrate.

4. A method as defined in claim 1 wherein the blood is heparinized blood.

5. A method as defined in claim 4 wherein:

the citrate is approximately a 3.8% sodium citrate concentration,

the inhibitor is prostacyclin, and

the prostacyclin is present in an approximate amount of 10 nanograms per milliliter of heparinized blood collected.

6. A method as defined in claim 4 wherein:

the citrate is approximately a 3.8% sodium citrate concentration,

the inhibitor is imidazole, and

the imidazole is present in an approximate concentration of 50 mM in the citrate.

7. A method of inhibiting a platelet-related procoagulant activity in a sample of whole blood collected from a patient in a collection medium including a calcium chelating agent, which platelet-related procoagulant activity would normally develop as a result of drawing the blood sample from the patient and conclude within approximately thirty minutes after the blood sample was drawn, comprising the steps of:

mixing an inhibitor of the platelet procoagulant activity with the blood sample approximately simultaneously with collecting the sample in the collection medium, the inhibitor comprising one of the group consisting of a prostaglandin or an inhibitor of thromboxane A2 synthesis.

8. A method as defined in claim 7 wherein the prostaglandin is prostacyclin.

9. A method as defined in claim 8 wherein:

the prostacyclin is present in the collection medium in an approximate concentration of 10 nanograms per milliliter of blood to be collected, and

the calcium chelating agent is sodium citrate present in the collection medium in an approximately concentration of 3.8%.

10. A method as defined in claim 7 wherein the inhibitor of thromboxane A2 synthesis is imidazole.

11. A method as defined in claim 10 wherein:

the imidazole is present in the collection medium in the approximate concentration of 50 mM, and

the calcium chelating agent is sodium citrate present in the collection medium in an approximate concentration of 3.8%.

12. A collection medium for whole blood and which is operative for inhibiting a platelet-related procoagulant activity in a sample of whole blood collected from a patient in the medium, the platelet-related procoagulant activity being one which would normally develop as a result of drawing the blood from the patient and conclude within approximately thirty minutes after the blood sample is drawn, the collection medium comprising:

a container in which to collect the blood sample,

a calcium chelating agent contained within the container to mix with the blood sample when collected, and

an inhibitor of the procoagulant activity comprising one of the group consisting of a prostaglandin or an inhibitor of thromboxane A2 synthesis.

13. A collection medium as defined in claim 12 wherein the inhibitor is a prostaglandin, and prostaglandin is a prostacyclin.

14. A collection medium as defined in claim 13 wherein:

the prostacyclin is present in an approximate concentration of 10 nanograms per milliliter of blood to be collected, and

the calcium chelating agent is sodium citrate present in an approximate concentration of 3.8%.

15. A collection medium as defined in claim 12 wherein the inhibitor of thromboxane A2 synthesis comprises imidazole.

16. A collection medium as defined in claim 15 wherein the calcium chelating agent is sodium citrate, and the imidazole is present in the approximate amount of 10.125 grams per 100 ml. of 3.8% concentration sodium citrate.